Investors

About us

Investors

About us

A vertebral fracture occurs somewhere in the world every 22 seconds. Vertebral fractures play an important and little known role in back pain, and 100,000 patients suffer from it each year in France. However, only one in three vertebral fractures are clinically diagnosed. [1]

Vexim is a specialist in the design and sale of minimally invasive solutions for the treatment of traumatic spine pathologies (low and high energy).

 

Based in Balma, near Toulouse, Vexim is an innovative company in the medical devices field, created and founded in 2006 by the investment fund Truffle Capital.

 

Since October 24th, 2017, Vexim is part of Stryker.

 

Our mission: To provide both physicians and patients with best in class treatment options.

Vexim has developed Masterflow™: a unique solution providing a controlled high viscosity cement injection, at a safe distance from radiations for multi-level procedures.
Vexim sells orthopaedic cement: Cohesion® Bone Cement.

 

From 2011, the figures speak for themselves on the success of Vexim:

 

 

And Vexim’s ambition does not stop there as its CEO, Vincent Gardès, seeks to capture 10% of the global market and attain a turnover of Eur 100 million within 5 years.

 

Vexim is backed financially by its shareholders: Truffle Capital, BPI (Banque Public d’Investissement), Kreaxi (formally Banexi Ventures Partners).

 

Governance Board

Stock Information
  1. Silverman SL. The clinical consequences of vertebral compression fracture. Bone 1992;13 Suppl2:S27-31
  2. Products Legal Notices